Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial

INTRODUCTION: There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Emilio, Garcia- Alonso, Fernando, Boldeanu, Anca, Baleeiro Teixeira, Thaïs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169657/
https://www.ncbi.nlm.nih.gov/pubmed/30282677
http://dx.doi.org/10.1136/bmjopen-2017-020242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169657/
https://www.ncbi.nlm.nih.gov/pubmed/30282677
http://dx.doi.org/10.1136/bmjopen-2017-020242

Ejemplares similares